|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.93 USD | +9.66% |
|
+15.57% | -35.88% |
| 05-15 | Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M | MT |
| 05-14 | Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex | MT |
Fortress Biotech, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 0.192 million compared to USD 0.268 million a year ago. Revenue was USD 75.74 million compared to USD 68.79 million a year ago.
Net loss was USD 86.58 million compared to USD 64.7 million a year ago. Basic loss per share from continuing operations was USD 14.55 compared to USD 11.85 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -35.88% | 33.85M | |
| -2.32% | 92.59B | |
| +3.68% | 41.43B | |
| -10.90% | 33.49B | |
| -19.56% | 14.62B | |
| -9.06% | 12.77B | |
| -11.34% | 11.58B | |
| -43.53% | 11.35B | |
| +3.75% | 8.97B | |
| -6.32% | 8.3B |
FORTRESS BIOTECH, INC. 